New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2013
15:02 EDTENDP, VRX, WCRXSources: Endo Health talks with potential buyers, Reuters says
Endo Health Solutions Inc (ENDP) has held exploratory talks with potential buyers in recent weeks, says Reuters, adding that the talks included interested parties like Warner Chilcott(WCRX) and Valeant Pharmaceuticals (VRX), according to the sources. Reference Link
News For ENDP;WCRX;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 22, 2015
14:03 EDTENDPAuxilium to host special shareholder meeting
Subscribe for More Information
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
18:27 EDTENDPOn The Fly: After Hours Movers
UP AFTER EARNINGS: eBay (EBAY), up 2.9%... United Rentals (URI), up 1.5%. ALSO HIGHER: Minerva (NERV), up 16.1% after reporting positive Phase 1 data with MIN-202... Endo (ENDP), up 3.1% after it was announced that Endo will replace Covidien in S&P 500 as of 1/26 close... Covidien (COV) is up 1%. DOWN AFTER EARNINGS: F5 Networks (FFIV), down 15.8%... Xilinx (XLNX), down 6.1%... Discover Financial Services (DFS), down 3.3%... American Express (AXP), down 2.2%. ALSO LOWER: BioMarin (BMRN), down 2.5% after filing to sell 7.25M shares of common stock... Kinder Morgan (KMI), down 1.9% after announcing that it will acquire Hiland Partners for approximately $3B and reporting fourth quarter results... Cisco (CSCO), down 1.4% after Bloomberg reported that Oracle's (ORCL) Ellison said that Oracle's new Virtual Compute Appliance is cheaper than Cisco's product.
18:06 EDTENDPS&P announces changes to the S&P 500, MidCap 400, SmallCap 600 indices
Subscribe for More Information
17:19 EDTENDPBoston Beer to replace Endo in S&P 400 as of 1/26 close
Subscribe for More Information
17:18 EDTENDPEndo to replace Covidien in S&P 500 as of 1/26 close
12:30 EDTVRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
January 20, 2015
07:00 EDTENDPEndo price target raised to $98 from $86 at Piper Jaffray
Piper Jaffray raised its price target for Endo shares to $98 saying Xiaflex's market expansion opportunities are not fully appreciated by the broader market. It keeps an Overweight rating on the stock.
January 13, 2015
12:49 EDTVRXValeant CEO says 'unlikely' to work with Bill Ackman again
Subscribe for More Information
12:48 EDTVRXValeant CEO says will have a 'number of clean quarters in a row'
Valeant CEO Michael Pearson said on CNBC that his company will have a "number of clean quarters in a row" in an effort to dispute attacks on its business model.
10:56 EDTVRXValeant sees continuation of Q3 trends in Q4
Subscribe for More Information
10:46 EDTVRXValeant doesn't see need to 'push a large deal for sake of doing large deal'
Sees double digit organic growth in 2014, 2015 and beyond. Says business development a priority for cash flow. Sees pursuing small and medium sized deals. Says doesn't see a need to "push a large deal for the sake of doing a large deal." Comments made at the JP Morgan Healthcare Conference. Valeant shares are up 2.1% to $158.76 in morning trading.
10:39 EDTVRXValeant repeats FY15 EPS view $10.10-$10.40, revenue $9.2B-$9.3B
Subscribe for More Information
10:38 EDTVRXValeant repeats Q4 cash EPS view $2.55+ vs. previous view $2.45-$2.55
Repeats Q4 revenue view $2.1B-$2.3B. Sees Q4 adjusted cash flow from operations about $600M. Says absorbed additional negative Fx impact of ~$40M to revenue, ~10c to cash EPS. Says FDA submission for Vesneo on track for Q2. Sees submission for sub-micron loteprednol gel 0.38% in late Q3, early Q4, and expects to launch product in 3Q16. Sees filing NDA for Arestin LCM in 2H15. Sees >12% same store organic growth for total company in Q4, >10% for FY. Sees Bausch + Lomb organic growth >10% for FY. Sees continued strong performance from Jublia, other recent product launches. Strategic initiates for 2015 include 10%-12% organic growth, cash conversion rate of >90%, achieve $500M+ revenues for key launch programs, including Jublia, Ultra, Luzu, Retin-A Micro 0.08%, Onexton. Comments from slides being presented at the JP Morgan Healthcare Conference.
07:42 EDTVRXJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
07:39 EDTVRXAmerican Academy of Cosmetic Surgery to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use